Zymeworks - ZYME Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZYME shares.
View ZYME analyst ratings or view top-rated stocks.

8 brokerages have issued 1 year price objectives for Zymeworks' shares. Their ZYME share price forecasts range from $8.00 to $18.00. On average, they anticipate the company's stock price to reach $12.63 in the next year. This suggests a possible upside of 54.0% from the stock's current price.
View analysts price targets for ZYME or view top-rated stocks among Wall Street analysts.

Zymeworks' stock was trading at $7.86 at the beginning of 2023. Since then, ZYME stock has increased by 4.3% and is now trading at $8.20.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our ZYME earnings forecast.

Zymeworks Inc. (NYSE:ZYME) posted its quarterly earnings results on Tuesday, March, 7th. The company reported $4.65 EPS for the quarter, beating the consensus estimate of $4.62 by $0.03. The firm earned $402.49 million during the quarter, compared to the consensus estimate of $371.36 million. Zymeworks had a net margin of 30.15% and a trailing twelve-month return on equity of 49.27%.

ETFs with the largest weight of Zymeworks (NYSE:ZYME) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and iShares Biotechnology ETF (IBB).

9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

(ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

Zymeworks' stock is owned by many different retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (12.01%), Morgan Stanley (8.85%), Samsara BioCapital LLC (2.57%), Point72 Asset Management L.P. (1.19%), Sessa Capital IM L.P. (1.18%) and Granahan Investment Management LLC (1.17%). Insiders that own company stock include Ali Tehrani, Christopher Astle, Diana Hausman, Ecor1 Capital, Llc, James Priour, Kathryn O'driscoll, Neil A Klompas and Neil Josephson.
View institutional ownership trends.

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ZYME stock can currently be purchased for approximately $8.20.

Zymeworks (NYSE:ZYME) has a market capitalization of $525.14 million and generates $412.48 million in revenue each year. The company earns $124.34 million in net income (profit) each year or $1.77 on an earnings per share basis.

The company employs 455 workers across the globe.

Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The official website for the company is www.zymeworks.com. The company can be reached via phone at (302) 274-8744, via email at ir@zymeworks.com, or via fax at 604-737-7077.